Compare POWW & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | POWW | SABS |
|---|---|---|
| Founded | 1990 | 2014 |
| Country | United States | United States |
| Employees | 81 | 86 |
| Industry | Ordnance And Accessories | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 242.8M | 288.8M |
| IPO Year | N/A | N/A |
| Metric | POWW | SABS |
|---|---|---|
| Price | $1.96 | $3.76 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $2.40 | ★ $10.75 |
| AVG Volume (30 Days) | 496.3K | ★ 816.4K |
| Earning Date | 02-09-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $14.56 | N/A |
| Revenue Next Year | $0.50 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.08 | $1.60 |
| 52 Week High | $2.23 | $6.60 |
| Indicator | POWW | SABS |
|---|---|---|
| Relative Strength Index (RSI) | 43.03 | 49.26 |
| Support Level | $1.89 | $3.54 |
| Resistance Level | $1.98 | $4.11 |
| Average True Range (ATR) | 0.07 | 0.35 |
| MACD | -0.01 | 0.04 |
| Stochastic Oscillator | 23.08 | 30.91 |
Outdoor Holding Co Formerly AMMO Inc is the owner of GunBroker.com, the online marketplace serving the firearms and shooting sports industries, and a vertically integrated producer of high-performance ammunition and components. It engages in the design, manufacture, and market of ammunition products in the Shooting sports industry in the United States. The firm's product segment comprises Ammunition and Marketplace. The Ammunition segment engages in the design, production, and marketing of ammunition and ammunition component products and the marketplace segment consists of the GunBroker.com marketplace. The company generates the majority of its revenue from the Ammunition segment.
SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate, SAB-142, targets autoimmune Type 1 Diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. It is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.